Verve Therapeutics (VERV) Issues 2022 Guidance and Key Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
January 10, 2022 6:30 AM ESTVERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022
ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022
Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs
CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (Nasdaq: VERV), a biotechnology company pioneering a new approach... More
